Bryant Furlow

High-dose hyperfractionated thoracic radiotherapy can improve outcomes in LS-SCLC, a phase 3 trial suggests.

Hippocampal-sparing PCI can protect cognitive function in SCLC patients without increasing the risk of intracranial relapse, data suggest.

Patritumab deruxtecan (HER3-DXd) is effective in patients with previously treated, EGFR-mutant NSCLC, a phase 2 study suggests.

Chemotherapy alone may produce better outcomes than surgery plus chemotherapy in patients with mesothelioma, the MARS 2 trial suggests.

Researchers found that patients who used opioids regularly had a roughly 30% higher risk of lung cancer than patients who did not use opioids.

Oncology nurses have an important role to play — and a legal responsibility — to recognize and ameliorate inequities that could affect patient compliance and access to cancer care for patients with disabilities.

Quickly recognizing and intervening to manage chemotherapy reactions can be a matter of life or death; this review of the signs can help oncology nurses know how to respond.

Palliative medicine is not reserved for hospice care and should be integrated into clinical care early in a patient’s cancer journey, with clear and honest communication with patients and families about the process.

Scant research and poor understanding of rare cancers has led to dismal outcomes for many patients but genomic analyses and novel research collaborations offer new hope.

Cancer survivors face bias, confusion, and other barriers to pain medication access; oncology nurses can help them overcome these barriers.